{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:29:26Z","timestamp":1791595766458,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are autoimmune antibody-mediated diseases. Efgartigimod is a neonatal Fc receptor-targeting therapeutic that causes a reduction in the antibody titers. The efficacy and the safety of efgartigimod as an add-on therapy with intravenous methylprednisolone (IVMP) in patients with NMOSD and MOGAD were assessed in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 27 adult patients diagnosed with NMOSD or MOGAD were enrolled, with 13 patients treated with IVMP plus efgartigimod and 14 comparable controls treated with IVMP alone. Efgartigimod was administered intravenously at 10 mg\/kg at four doses or 20 mg\/kg at two doses. The Expanded Disability Status Scale (EDSS) scores, the serum immunoglobulin G (IgG) levels, and the pathogenic antibody titers were evaluated before and after therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with IVMP alone, the efgartigimod group achieved better outcome with EDSS reduction of 1.3 \u00b1 0.6 (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05) compared with the control group (0.5 \u00b1 0.5). In the efgartigimod-treated group, the serum IgG levels decreased by 69.8% after therapy (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), and nine patients (69.2%) showed a reduction in antibody titers. Moreover, the EDSS and antibody titers showed a rapid downward trend in the intensive therapy cohort (20 mg\/kg, two doses).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this preliminary study, efgartigimod add-on therapy showed better trends than IVMP alone in accelerating short-term recovery in patients with NMOSD and MOGAD at the acute phase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1793153","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:43:39Z","timestamp":1778564619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase"],"prefix":"10.3389","volume":"17","author":[{"given":"Weifan","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Clinical Medical Research Center for Stroke Prevention and Treatment of Hunan Province, Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shige","family":"Wang","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health, University of Manchester","place":["Manchester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Clinical Medical Research Center for Stroke Prevention and Treatment of Hunan Province, Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Clinical Medical Research Center for Stroke Prevention and Treatment of Hunan Province, Department of Neurology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01014-1","article-title":"Nmosd and mogad: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-007-2262-8","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577387","article-title":"Nmosd acute attack: understanding, treatment and innovative treatment prospect","volume":"348","author":"Ma","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105941","article-title":"New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD","volume":"92","author":"Kosior","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577604","article-title":"Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone","volume":"356","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616646332","article-title":"Immunoadsorption in patients with neuromyelitis optica spectrum disorder","volume":"9","author":"Faissner","year":"2016","journal-title":"Ther Adv Neurological Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.02.007","article-title":"Targeting FcRn for the modulation of antibody dynamics","volume":"67","author":"Ward","year":"2015","journal-title":"Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunolog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barre syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444288","article-title":"Case report: rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12556-1","article-title":"Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod","volume":"271","author":"Zhu","year":"2024","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30421","article-title":"Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: a case report","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07678-3","article-title":"Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report","volume":"45","author":"Huang","year":"2024","journal-title":"Neurol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s13023-024-03501-6","article-title":"Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders","volume":"19","author":"Yang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70190","article-title":"Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks","volume":"91","author":"Liu","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515617248","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2016","journal-title":"Mult Scler"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ene.15561","article-title":"Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks","volume":"30","author":"Wang","year":"2023","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1793153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:43:41Z","timestamp":1778564621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1793153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1793153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1793153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1793153"}}